Vaxart Provides Merger Update
February 09 2018 - 3:30PM
Business Wire
Vaxart, Inc., a clinical-stage biotechnology company developing
oral recombinant vaccines that are administered by tablet rather
than by injection, announced today it has reached an understanding
with the CAS Group under which East Hill, a major shareholder in
Aviragen, will support the merger between Vaxart and Aviragen.
“We are committed to creating significant value for all our
shareholders as evidenced by the amended terms of the merger that
were recently announced,” said Wouter W. Latour, M.D., chief
executive officer of Vaxart. “We want to thank all those who helped
in that process, including in particular the current Vaxart
shareholders.”
“We look forward to building a long term relationship with East
Hill, as with all our shareholders, and greatly appreciate their
support.”
About Vaxart
Vaxart is a clinical-stage company focused on developing oral
recombinant protein vaccines based on its proprietary oral vaccine
platform. Vaxart’s oral vaccines are designed to generate broad and
durable immune responses that protect against a wide range of
infectious diseases and may be useful for the treatment of chronic
viral infections and cancer. Vaxart’s oral vaccines are
administered using a convenient room temperature-stable tablet,
rather than by injection. Vaxart believes that tablet vaccines are
easier to distribute and administer than injectable vaccines, and
have the potential to significantly increase vaccination rates.
Vaxart’s development programs include oral tablet vaccines are
designed to protect against norovirus, seasonal influenza and
respiratory syncytial virus (RSV), as well as a therapeutic vaccine
for human papillomavirus (HPV), Vaxart’s first immuno-oncology
indication. For more information, please visit www.vaxart.com.
Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements about
Vaxart Inc. and its business, strategy and plans, including but not
limited to statements regarding its clinical drug development
activities, clinical results and trial designs. All statements
other than statements of historical facts included in this press
release are forward looking statements. The words “believes”,
“may,” “can,” “plans,” “estimates,”“will,” and any similar
expressions or other words of similar meaning are intended to
identify those assertions as forward-looking statements. These
forward-looking statements involve substantial risks and
uncertainties that could cause actual results to differ materially
from those anticipated. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. Except to the extent required by
applicable law or regulation, Vaxart undertakes no obligation to
update the forward-looking statements included in this press
release to reflect subsequent events or circumstances.
Additional Information and Where to Find It
In connection with a proposed strategic merger of Aviragen
Therapeutics (Nasdaq: AVIR) and Vaxart, Aviragen has filed relevant
materials with the Securities and Exchange Commission (SEC),
including a registration statement on Form S-4, as amended.
Investors may obtain the proxy statement/prospectus, as well as
other filings containing information about Aviragen, free of
charge, from the SEC’s web site (www.sec.gov). In addition,
investors and security holders may obtain free copies of the
documents filed with the SEC by Aviragen by directing a written
request to: Aviragen Therapeutics, Inc. 2500 Northwinds Parkway,
Suite 100, Alpharetta, GA 30009, Attention: Investor Relations.
Investors and security holders are urged to read the proxy
statement, prospectus and the other relevant materials when they
become available before making any voting or investment decision
with respect to the merger.
This communication shall not constitute an offer to sell or the
solicitation of an offer to sell or the solicitation of an offer to
buy any securities, nor shall there be any sale of securities in
any jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such jurisdiction. No offering of securities
shall be made except by means of a prospectus meeting the
requirements of Section 10 of the Securities Act of 1933, as
amended.
Participants in the Solicitation
Aviragen and its directors and executive officers and Vaxart and
its directors and executive officers may be deemed to be
participants in the solicitation of proxies from the stockholders
of Aviragen in connection with the proposed transaction.
Information regarding the special interests of these directors and
executive officers in the merger will be included in the proxy
statement/prospectus referred to above. Additional information
regarding the directors and executive officers of Aviragen is also
included in Aviragen Annual Report on Form 10-K for the year ended
December 31, 2016. This document is available free of charge at the
SEC web site (www.sec.gov) and from Investor Relations at Aviragen
at the address set forth above.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180209005713/en/
W2OKatie Hogan, 415-658-9745khogan@wcgworld.comorVaxart,
Inc.Emery Dora, 650-550-3514edora@vaxart.com
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Sep 2023 to Sep 2024